Total Funding
41
70
Total FundingPost-IPO Equity raised
Growth Score
-7 pts
Heat Score
3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
63813
Biohaven is a biopharmaceutical company that develops drug candidates targeting neurological diseases.
- Rob Berman: Co-Founder and Strategic AdvisorPast Role: Biohaven Pharmaceutical, CMO
- James Engelhart: Chief Financial OfficerPast Role: Energizer Holdings, Finance Director, Global Financial Planning and Analysis
About the Company
Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline
products include BHV3000-301, BHV3000-302, BHV3000-303, and others.
